secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2026-08-05T11:17:09+00:00
Accession:  0001005286-26-000032
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Q2 revenue $34.2M, down 6.2% YoY; net loss $6.2M vs $1.1M loss last year
--------------------------------------------------------------------------------

- Revenue $34.2M, down 6.2% YoY; net loss $6.2M ($0.19 loss per share) vs $1.1M loss ($0.06) in prior year.
- Adjusted EBITDA $8.6M, down from $9.1M; free cash flow $0.9M for six months ended June 30, 2026.
- Reaffirmed 2026 guidance; targeting 12% revenue CAGR and >25% Adjusted EBITDA margin by end of 2029.
- Added 13 new programs in past 12 months, including 8 late-stage; 6 new programs signed in Q2 2026.
- Ended Q2 with $38.8M liquidity ($17.2M cash, $21.6M revolver availability).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/0001005286-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/lfcr-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001005286-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer